Alkermes is a biopharmaceutical company focused on developing medicines for complex neurological and psychiatric disorders. The company employs its neuroscience expertise to create innovative treatment options.

Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Dec 6, 2024 12:50 AM	605d20c8
public peers	general	Oct 16, 2024 6:08 AM	ce772344
news daily refresh	general	Dec 4, 2024 2:16 PM	d4e2d2e8
news processing daily refresh	general	Dec 5, 2024 4:11 AM	4549b186
news impact assignment daily	general
news processing basic	general	Dec 5, 2024 4:11 AM	0dbc5c4f
company summary	general
signals	general	Oct 16, 2024 6:08 AM	1e269d8f
crunchbase trigger	general	Nov 27, 2024 12:50 PM	2251a911
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Oct 16, 2024 6:08 AM	ef3bc578
news basic	general	Dec 4, 2024 2:13 PM	27d0bd3d
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ALKERMES

Alkermes

Last Close

27.70

22/11 21:00

Market Cap

3.89B

Beta: -

Volume Today

402

Avg: -